{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:16:08Z","timestamp":1783563368550,"version":"3.55.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australia\u2019s Medical Research Future Fund","award":["RFRHPI000017"],"award-info":[{"award-number":["RFRHPI000017"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cystic fibrosis (CF) is the most prevalent serious inherited disease in Australia, imposing significant health risks. CF is characterized by chronic lung inflammation and recurrent pulmonary infections that increase morbidity and premature mortality rates. The emergence of antimicrobial resistance (AMR) places further challenges on the treatment and management of CF, necessitating research into alternative strategies for treatment of bacterial infections. Bacteriophage therapy, involving bacterial-specific viruses, is a potential avenue for AMR infections in patients with CF. Existing literature supports the feasibility of phage therapy in CF but there has been a gap in investigating attitudes of the CF community including affected individuals and their caregivers, regarding phage therapy. Understanding perspectives and needs of the CF community is essential for successful implementation and acceptance of novel therapies including phage therapy. We conducted a survey that encompasses responses from 112 consumers from across Australia, comprising people living with CF (38.4%), parents of affected children (49.6%), carers (6.4%), and family members (3%). The findings showed a significant reliance on antibiotics with 51.4% requiring oral, 43.4% nebulized, and 11.4% intravenous antibiotics within the preceding 2 weeks. Respondents highlighted the availability of new treatments, duration of hospitalizations and costs associated with treatment as important priorities to address. Despite an awareness of phage therapy among 62.4% of respondents, 86.4% expressed interest in obtaining more information, primarily from medical staff (66.7%). Notably, 96.0% of respondents expressed willingness to participate in phage therapy trials. The results of this survey highlighted the CF community\u2019s strong interest in advanced therapeutic approaches, specifically phage therapy. The findings reveal a notable recognition and acceptance of phage therapy as a viable treatment option for pulmonary infections associated with CF. This study addresses UN Sustainable Development Goal 3: Good Health and Wellbeing by advancing knowledge on alternative therapeutic strategies for managing AMR in CF. By exploring community attitudes towards bacteriophage therapy, the research promotes informed development and implementation of innovative, targeted treatments for CF-associated infections. These findings support the sustainable management of AMR, fostering better health outcomes and reducing reliance on traditional antibiotics, thereby contributing to long-term health resilience.<\/jats:p>","DOI":"10.1093\/sumbio\/qvae036","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T01:05:19Z","timestamp":1737767119000},"source":"Crossref","is-referenced-by-count":2,"title":["Policy in practice: Cystic Fibrosis Australia and Phage Australia surveys: understanding clinical needs and attitudes towards phage therapy in the cystic fibrosis community"],"prefix":"10.1093","volume":"2","author":[{"given":"Stephanie","family":"Lynch","sequence":"first","affiliation":[{"name":"Phage Australia at Westmead Institute for Medical Research , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, The University of Sydney , Camperdown, NSW 2050 ,","place":["Australia"]},{"name":"Westmead Hospital, Western Sydney Local Health District , Westmead, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Phage Australia at Westmead Institute for Medical Research , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, The University of Sydney , Camperdown, NSW 2050 ,","place":["Australia"]},{"name":"Westmead Hospital, Western Sydney Local Health District , Westmead, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Khatami","sequence":"additional","affiliation":[{"name":"Phage Australia at Westmead Institute for Medical Research , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, The University of Sydney , Camperdown, NSW 2050 ,","place":["Australia"]},{"name":"The Children\u2019s Hospital Westmead, Sydney Childrens Hospital Network , Westmead, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicki","family":"Mileham","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Australia , North Ryde, NSW 2114 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C","family":"Sacher","sequence":"additional","affiliation":[{"name":"Phage Australia at Westmead Institute for Medical Research , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Westmead Hospital, Western Sydney Local Health District , Westmead, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Phage Australia at Westmead Institute for Medical Research , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Westmead Hospital, Western Sydney Local Health District , Westmead, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-511X","authenticated-orcid":false,"given":"Ruby C Y","family":"Lin","sequence":"additional","affiliation":[{"name":"Phage Australia at Westmead Institute for Medical Research , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, The University of Sydney , Camperdown, NSW 2050 ,","place":["Australia"]},{"name":"Westmead Hospital, Western Sydney Local Health District , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"School of Medical Sciences, University of New South Wales , Sydney, NSW 2033"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Iredell","sequence":"additional","affiliation":[{"name":"Phage Australia at Westmead Institute for Medical Research , Westmead, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, The University of Sydney , Camperdown, NSW 2050 ,","place":["Australia"]},{"name":"Westmead Hospital, Western Sydney Local Health District , Westmead, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2025021207441977200_bib2","first-page":"2519","article-title":"Australian Cystic Fibrosis Data Registry annual report, 2020","author":"Ahern","year":"2021"},{"key":"2025021207441977200_bib3","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in three lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am J Transplant"},{"key":"2025021207441977200_bib4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12890-016-0339-5","article-title":"Cystic fibrosis lung environment and Pseudomonas aeruginosa infection","volume":"16","author":"Bhagirath","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2025021207441977200_bib6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2217\/fmb.13.47","article-title":"Phage cocktails and the future of phage therapy","volume":"8","author":"Chan","year":"2013","journal-title":"Future Microbiology"},{"key":"2025021207441977200_bib7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"2025021207441977200_bib8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025021207441977200_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1542\/pir.2019-0212","article-title":"Cystic fibrosis","volume":"42","author":"Dickinson","year":"2021","journal-title":"Pediatr Rev\/Am Acad Pediatr"},{"key":"2025021207441977200_bib10","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2025021207441977200_bib11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1751-7915.2011.00259.x","article-title":"Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens","volume":"4","author":"Kvachadze","year":"2011","journal-title":"Microb Biotechnol"},{"key":"2025021207441977200_bib12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"2025021207441977200_bib13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/v13010060","article-title":"A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient","volume":"13","author":"Lebeaux","year":"2021","journal-title":"Viruses"},{"key":"2025021207441977200_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"key":"2025021207441977200_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3947\/ic.2023.0067","article-title":"Phage therapy in Korea: a prescribers\u2019 Survey of attitudes amongst Korean infectious diseases specialists towards Phage therapy","volume":"56","author":"Lee","year":"2024","journal-title":"Infect Chemother"},{"key":"2025021207441977200_bib16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5694\/mja2.51797","article-title":"Diagnosis of cystic fibrosis in adults: Australian Cystic Fibrosis Data Registry data, 2000\u20132019","volume":"218","author":"Lin","year":"2023","journal-title":"Med J Aust"},{"key":"2025021207441977200_bib17","doi-asserted-by":"publisher","first-page":"e0285824","DOI":"10.1371\/journal.pone.0285824","article-title":"Phage therapy and the public: increasing awareness essential to widespread use","volume":"18","author":"McCammon","year":"2023","journal-title":"PLoS One"},{"key":"2025021207441977200_bib18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/cid\/ciac117","article-title":"The rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting Elexacaftor-Tezacaftor-Ivacaftor","volume":"75","author":"Miller","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025021207441977200_bib19","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/ppul.20873","article-title":"Shifting patterns of inhaled antibiotic use in cystic fibrosis","volume":"43","author":"Moskowitz","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"2025021207441977200_bib20","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","article-title":"Case study: host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection","volume":"185","author":"Nick","year":"2022","journal-title":"Cell"},{"key":"2025021207441977200_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamaoto.2019.1191","article-title":"Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus","volume":"145","author":"Ooi","year":"2019","journal-title":"JAMA Otolaryngol\u2014Head Neck Surg"},{"key":"2025021207441977200_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1128\/CMR.00019-18","article-title":"Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis","volume":"31","author":"Parkins","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2025021207441977200_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/antibiotics12020217","article-title":"Antibiotic resistance in patients with cystic fibrosis: past, present, and future","volume":"12","author":"Perikleous","year":"2023","journal-title":"Antibiotics"},{"key":"2025021207441977200_bib24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","article-title":"Safety of bacteriophage therapy in severe Staphylococcus aureus infection","volume":"5","author":"Petrovic","year":"2020","journal-title":"Nat Microbiol"},{"key":"2025021207441977200_bib25","article-title":"Attitudes to phage therapy among Australian infectious diseases physicians","author":"Plymoth","year":"2023","journal-title":"Medrxiv"},{"key":"2025021207441977200_bib27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjresp-2022-001360","article-title":"Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and","volume":"10","author":"Singh","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"2025021207441977200_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/resp.12714","article-title":"Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres","volume":"21","author":"Smith","year":"2016","journal-title":"Respirology"},{"key":"2025021207441977200_bib29","first-page":"12","article-title":"Prophylactic antibiotics for cystic fibrosis","volume":"3","author":"Smyth","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"2025021207441977200_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","article-title":"Phage therapy: from biological mechanisms to future directions","volume":"186","author":"Steffanie","year":"2023","journal-title":"Cell"},{"key":"2025021207441977200_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","article-title":"Bacteriophage therapy","volume":"45","author":"Sulakvelidze","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2025021207441977200_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-022-07047-5","article-title":"Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b\/2, multicenter, randomized, double-blind, placebo-controlled trial","volume":"23","author":"Tamma","year":"2022","journal-title":"Trials"},{"key":"2025021207441977200_bib33","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ppul.22652","article-title":"Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis","volume":"48","author":"Wagener","year":"2013","journal-title":"Pediatr Pulmonol"}],"container-title":["Sustainable Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sumbio\/advance-article-pdf\/doi\/10.1093\/sumbio\/qvae036\/61622864\/qvae036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sumbio\/article-pdf\/2\/1\/qvae036\/61622864\/qvae036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sumbio\/article-pdf\/2\/1\/qvae036\/61622864\/qvae036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:44:35Z","timestamp":1739346275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sumbio\/article\/doi\/10.1093\/sumbio\/qvae036\/7979009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/sumbio\/qvae036","relation":{},"ISSN":["2755-1970"],"issn-type":[{"value":"2755-1970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"qvae036"}}